Ipamorelin

A highly selective growth hormone secretagogue that stimulates GH release from the pituitary via the ghrelin receptor (GHS-R1a). Ipamorelin is particularly relevant to sleep because the largest natural GH pulse occurs during deep slow-wave sleep. By amplifying this pulse when administered before bedtime, Ipamorelin enhances sleep quality, promotes overnight recovery, and deepens restorative sleep phases — all without significantly affecting cortisol or prolactin levels.

• Selective agonism of GHS-R1a (ghrelin receptor) in the anterior pituitary
• Amplifies endogenous GHRH-driven GH pulsatility during slow-wave sleep
• Does not suppress somatostatin, preserving natural GH feedback regulation
• Minimal effect on cortisol, prolactin, and aldosterone (high selectivity)

• Active cancer or history of malignancy (GH promotes cell proliferation)
• Diabetes — monitor blood glucose (GH can elevate fasting glucose)
• Pregnancy or breastfeeding
• Active pituitary disorders

Store at 2–8°C (36–46°F) for up to 3 months. Once reconstituted, refrigerate and use within 21-28 days. Do not freeze after reconstitution.

Ipamorelin was developed by Novo Nordisk and has been studied in multiple Phase 1 and Phase 2 trials. A key study demonstrated dose-dependent GH release with remarkable selectivity — no significant changes in ACTH, cortisol, prolactin, or TSH at effective GH-releasing doses. Clinical trials for post-surgical ileus (bowel recovery) used IV administration successfully. Sleep-specific research shows that GH secretagogues administered before bedtime increase slow-wave sleep duration by 20-50% in both young and older adults. Ipamorelin's clean side-effect profile makes it the preferred GH peptide for sleep optimization among researchers and clinicians.